Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor
cells has been implicated in triggering a complex signal cascade that leads to increased …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is
used in cancer treatment. Although development of resistance to cetuximab is well …

ABSTRACT Introduction: Epidermal Growth Factor Receptor (EGFR)-dependent signaling
plays a crucial role in epithelial cancer biology, and dictated the development of several …

Recent progress in molecular biology and translational research has initiated an era of
personalized medicine in head and neck clinical oncology. The genetic information defined …

Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …

Background: Despite the improvement in clinical outcomes for head and neck squamous
cell carcinoma (HNSCC) as the result of cetuximab, patients may present with or develop …

Background To investigate the safety and activity of cetuximab in the pre-operative treatment
of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods …

EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC).
Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation …

Background Only a subset of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre-and
post-therapy tumor biopsies (windows studies) in treatment-naïve patients are crucial to …